Early measurable residual disease clearance is linked to better outcomes in acute myeloid leukemia, study suggests.

AML: Acute myeloid leukemia; CLL: C-type lectin-like molecule; CXCR: CXC chemokine receptor; N/A: Not applicable; NF: Nuclear factor. Acute myeloid leukemia (AML) remains incurable for the ...

Good day, everyone, and welcome to today's Q4 2024 Kura Oncology, Inc., financial results conference call. (Operator Instructions) Please note this call is being recorded. It is now my pleasure to ...

Today, OGT announces the North American launch of its new next-generation sequencing (NGS) SureSeq ™ Myeloid MRD Panel, which provides a flexible NGS workflow for the detection of ultra-low ...

Kura Oncology's (KURA) ziftomenib shows AML promise amid competition. See why I'm inclined to view the current price levels ...

Dr. Meshinchi serves as director of the largest genome and transcriptome sequencing project in pediatric and young adult AML and has created a robust ... aberrations after initial therapy (minimal ...

KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint – – Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR ...

We believe these advancements could meaningfully accelerate the development and commercialization of ziftomenib in frontline AML with top-line results from the MRD-negative CR accelerated endpoint ...